PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23243024-8	2013	Furthermore, we show that a nontoxic compound, cannabidiol, significantly downregulates Id-1 gene expression and associated glioma cell invasiveness and self-renewal.	Cannabidiol	47-58	inhibitor of DNA binding 1, HLH protein	Homo sapiens	88-92	
18025276-0	2007	Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.	Cannabidiol	0-11	inhibitor of DNA binding 1, HLH protein	Homo sapiens	36-40	
20859676-5	2011	We previously reported that cannabidiol (CBD), a cannabinoid with a low toxicity profile, down-regulated Id-1 gene expression in aggressive human breast cancer cells in culture.	Cannabidiol	28-39	inhibitor of DNA binding 1, HLH protein	Homo sapiens	105-109	
20859676-5	2011	We previously reported that cannabidiol (CBD), a cannabinoid with a low toxicity profile, down-regulated Id-1 gene expression in aggressive human breast cancer cells in culture.	Cannabidiol	41-44	inhibitor of DNA binding 1, HLH protein	Homo sapiens	105-109	
18025276-7	2007	Here, we report that cannabidiol (CBD), a cannabinoid with a low-toxicity profile, could down-regulate Id-1 expression in aggressive human breast cancer cells.	Cannabidiol	21-32	inhibitor of DNA binding 1, HLH protein	Homo sapiens	103-107	
18025276-7	2007	Here, we report that cannabidiol (CBD), a cannabinoid with a low-toxicity profile, could down-regulate Id-1 expression in aggressive human breast cancer cells.	Cannabidiol	34-37	inhibitor of DNA binding 1, HLH protein	Homo sapiens	103-107	
18025276-12	2007	In conclusion, CBD represents the first nontoxic exogenous agent that can significantly decrease Id-1 expression in metastatic breast cancer cells leading to the down-regulation of tumor aggressiveness.	Cannabidiol	15-18	inhibitor of DNA binding 1, HLH protein	Homo sapiens	97-101	
33912679-1	2021	Background: We previously reported that cannabidiol (CBD), a cannabinoid with a low toxicity profile, downregulated the expression of the prometastatic gene inhibitor of DNA binding 1 (ID1) in cancer cells, leading to inhibition of tumor progression in vivo.	Cannabidiol	40-51	inhibitor of DNA binding 1, HLH protein	Homo sapiens	185-188	
35605606-5	2022	In vitro and in vivo genetic and pharmacologic (cannabidiol (CBD)) inhibition of ID1 on DMG tumor growth was assessed.	Cannabidiol	48-59	inhibitor of DNA binding 1, HLH protein	Homo sapiens	81-84	
35605606-5	2022	In vitro and in vivo genetic and pharmacologic (cannabidiol (CBD)) inhibition of ID1 on DMG tumor growth was assessed.	Cannabidiol	61-64	inhibitor of DNA binding 1, HLH protein	Homo sapiens	81-84	
35605606-13	2022	CONCLUSIONS: H3K27M-mediated re-activation of ID1 in DMG results in a SPARCL1+ migratory transcriptional program that is therapeutically targetable with CBD.	Cannabidiol	153-156	inhibitor of DNA binding 1, HLH protein	Homo sapiens	46-49	
33912679-1	2021	Background: We previously reported that cannabidiol (CBD), a cannabinoid with a low toxicity profile, downregulated the expression of the prometastatic gene inhibitor of DNA binding 1 (ID1) in cancer cells, leading to inhibition of tumor progression in vivo.	Cannabidiol	53-56	inhibitor of DNA binding 1, HLH protein	Homo sapiens	185-188	
32410828-10	2020	Numerous drugs were found exerting their anti-tumor function through Id1-related signaling pathways, such as fucoidan, berberine, tetramethylpyrazine, crizotinib, cannabidiol and vinblastine.	Cannabidiol	163-174	inhibitor of DNA binding 1, HLH protein	Homo sapiens	69-72